| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Outrun Therapeutics Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases. 163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 10 |
 | Kano Therapeutics Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering 113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 16 |
 |  LinKinVax LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology. 161 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 2 |
 | Vivet Therapeutics Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy 91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 20 |
 | Genvade Therapeutics Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne 101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | N/A |
 | Neocor Therapeutics Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology 118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 4 |
 |  Astraveus We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing 428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 64 |
 | Integra Therapeutics Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery. 112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 22 |
 | PulseSight Therapeutics PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapies with minimally-invasive delivery technology to treat major eye diseases. Our mission is to develop life-changing solutions for patients with diseases leading to sight loss. 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 9 |
 | GENEPEP - PEPTIDE Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc... 375 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 14 |
 | Coave Therapeutics Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success … 86 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 10 | 41 |
 | Regulaxis SAS Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its … 251 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | AAVantgarde Bio Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases 338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 1 | 51 |
 | Polyneuron Pharmaceuticals AG Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients. 129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 4 |
 | AveXis, Inc. AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy 68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 107 |
 | RhyGaze AG Innovating vision RhyGaze AG is pioneering a transformative approach with cone optogenetics, which has the potential to revolutionize vision restoration for patients suffering from blindness. pharmaceutical development, optogenetics, gene therapy, ophthalmology, and pharmaceutical research 118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 10 |
 | Camena Bioscience Unlocking access to genes with unparalleled accuracy Our mission is to enable synthetic biologists, by using our technology to unlock access to genes with unparalleled accuracy. We produce genes for a range of biotechnology customers including those in the pharmaceutical, agriculture and diagnostics sectors. Our technology offers access to long and complex gene sequences, which are normally difficult to produce. We are based in Cambridge UK, but we serve companies across the world. Camena's technology is positioned to enable researchers and the synthetic biology revolution. Twitter: @camenabio DNA synthesis, Complex genes, Synthetic Biology, synbio, and Gene synthesis 110 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 31 |
 | 64x Bio An evolution in cell line engineering. High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics 171 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 22 |
 | Harness Therapeutics Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP 279 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 32 |
 | Immitra Bio GmbH We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable. 221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 4 |
 | BioNTech IMFS BioNTech Innovative Manufacturing Services (IMFS) is a subsidary of BioNTech SE. We are specialized in the development and production of innovative products (viral vectors, cells and ivt mRNA). Based on extensive expertise in scientific, technical and regulatory prerequisites, we develop and manufacture your products in a safe and cost-efficient way in our state-of-the-art GMP facilities. We offer contract services for retroviral vector manufacturing for clinical supply. The company has more than 500 experienced and highly skilled employees and is always looking for motivated people! See also www.biontech-imfs.de Cell therapy, GMP manufacturing, Gene Therapy, RNA manufacturing, Retroviral vector manufacturing, Contract Manufacturing, … 115 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 255 |
 | Adaptyv Next-generation protein engineering Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design. 90 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 20 |
 | Aurion Biotech We're on a mission to cure blindness with our transformational platform of advanced therapies Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 87 |
 | MaxCyte, Inc. Let's Build Better Cells Together We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, … 313 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 131 |
 | Sensible Biotechnologies Unlocking the next generation of mRNA medicines. At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity. 109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 21 |
 | HHC medical Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies 408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 2 | 47 |
 | Pencil Biosciences Limited Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing 299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 15 |
 | Virax Biolabs Innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. medical device development, medical device distribution, Logistics, Procurement, Distribution, IOTH, Innovation, T-Cells, and immunology 133 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 0 | 30 |
 | Evonetix Ltd Technology to ignite the biology revolution We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible. Biotechnology, Synthetic Biology, DNA synthesis, Gene synthesis, and synbio 165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 21 |
 | PepGen Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics 436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 89 |
 | Fuse Vectors Catalyzing Gene Therapy | Revolutionary Technology for Revolutionary Therapies At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time. 35 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology | 0 | 12 |
 | MEDIBIOFARMA SL To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
 | Invitris A startup using Synthetic Biology to innovate the way we develop entirely novel classes of protein-based drugs. Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, such as the next generation of antibiotics. 126 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 18 |
 | Senti Biosciences Outsmarting complex diseases with more intelligent medicines Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell … 82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 60 |
 | Acceleron Pharma Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases 605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 6 | 67 |
 | Genewity B.V. Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field. 275 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 14 |
 | Astellas Gene Therapies Follow Astellas Pharma for updates on our pipeline of genetic medicines for patients with rare diseases. The Astellas Gene Therapies page is no longer active or monitored. gene therapy and biotechnology 59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 406 |
 | MiNA Therapeutics Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery 213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 35 |
 | AVROBIO Clinical-stage lentiviral gene therapy company, powered by plato®. Our vision: bring personalized gene therapy worldwide Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. … 45 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 20 |
 | Voyager Therapeutics, Inc. Breaking through barriers in gene therapy and neurology Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of … 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 194 |
 | ReCode Therapeutics Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology 88 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology | 4 | 117 |
 |  GENZ Biotechnology Developing novel IVD solutions Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients and our shareholders. To date, Genz developed 4 IVD diagnostic tests commercially legalized, attended International joint projects, partnered with top research centers in the world and published several scientific articles in international scientific journals. Biotechnology, Genetik … 161 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | VRG Therapeutics Regional leader in preclinical R&D with a world-class protein evolution tech platform for CGT applications Our mission is to cure diseases via targets and MoAs that cannot be reached with traditional approaches. Leveraging our unique platform, we optimize peptides/proteins of natural origin using directed evolution to create cutting-edge CGT products or peptide-based pharmaceuticals. VRGT’s management and staff members were selected based on their international research experience and outstanding pharma industry achievements. Our people have outstanding professional expertise in preclinical/clinical R&D and scientific project management, pharmacology, business development and medical marketing. For years, they have worked in the most prestigious academic … 158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 26 |
 | Casebia Therapeutics An innovative gene editing company discovering and developing curative treatments for genetic diseases Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing … 82 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 0 | 1 |
 | NewBiologix Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines 288 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 22 |
 | Kernal Biologics KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy 108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 15 |
 | Ethris Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform. Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing 87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 52 |
 | Foghorn Therapeutics Inc. Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. 70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 128 |
 | REGENXBIO Seeking to improve lives through the curative potential of gene therapy. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with … 14 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS | 1 | 373 |
 | SIRION BIOTECH GmbH (Revvity Gene Delivery) Any Gene to Any Cell Viral Vector Services from Vector Engineering and Manufacturing to Cell and Gene Therapy Development Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. Whether you need small scale viral production or full scale viral vector optimization and manufacture, our expert team has you covered. For additional information, please visit www.sirion-biotech.com. AAV, Lentivirus, Custom viral vectors, Virus production, AAV engineering for gene therapy, LentiBOOST, and Gene delivery 64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 3,204 |
 | uniQure Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease 160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 334 |
 | Spur Therapeutics Toward the next generation of gene therapy. Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter … 88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 329 |